SynAct Pharma (SYNACT) CMD 2026 summary

Corporate and strategic update

• Transitioning from a waiting position to active business development, with key data from three clinical programs expected in the next two quarters, driving potential partnerships and value creation.

• Dual-track strategy focuses on both autoimmune (rheumatoid arthritis) and viral respiratory indications, de-risking the pipeline and broadening partnering opportunities.

• Financially well-positioned, with funding secured into Q3 2027, enabling negotiation leverage and strategic flexibility.

• Management team strengthened with new CBO and CFO, both bringing significant deal-making and financial expertise.

• Active engagement with potential partners globally, with major partnering events and conferences targeted for upcoming data releases.

Rheumatoid arthritis (RA) program and market positioning

• Lead compound Resomelagon targets early RA patients with high disease activity, aiming to provide a non-immunosuppressive, pro-resolution therapy that could reduce reliance on glucocorticoids and delay or prevent biologic use.

• ADVANCE Phase IIb study completed recruitment (246 patients); top-line data expected in June, with primary endpoint DAS28-CRP and key secondary endpoints including ACR20 and HAQ.

• Previous studies (BEGIN, EXPAND) showed rapid, clinically meaningful reductions in disease activity, especially in newly diagnosed, high-CRP patients, with favorable safety profile and no signs of immunosuppression.

• RA market is large and growing, dominated by biologics and JAK inhibitors; innovation in pro-resolution therapies is attracting significant pharma interest.

• Multiple deal structures possible, with licensing (global or regional) and potential asset sales; active discussions with major pharma players in RA and adjacent spaces.

Host-directed therapies for respiratory infections

• Host-directed therapy approach aims to modulate inflammation in severe viral respiratory infections (influenza, RSV, COVID-19), addressing a major unmet need in hospitalized patients.

• Clinical data in COVID-19 showed faster respiratory recovery and shorter hospital stays; ongoing Phase II studies in Europe (RESPIRE) and Brazil (RESOVIR-2 for dengue) target broader validation.

• Market opportunity is significant, with over one million annual hospitalizations in the US and Europe for viral respiratory infections; economic burden is high due to prolonged hospital stays and ICU use.

• Regulatory and payer focus is shifting toward host-directed therapies, with authorities like NIAID prioritizing innovation beyond antivirals.

• Fewer deals in respiratory than autoimmune, but recent high-value transactions (e.g., $9B for a phase III influenza antiviral) highlight growing interest.